VISTIN PHARMA ASA financials
VISTIN PHARMA ASA
5967007LIEEXZXFQY092 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 429.1M | NOK 435.4M |
| Other income | NOK 412.0K | NOK 2.9M |
| Employee benefits expense | NOK 94.2M | NOK 93.1M |
| Raw materials & consumables used | NOK 150.0M | NOK 176.6M |
| Operating profit (EBIT) | NOK 85.3M | NOK 68.6M |
| Finance costs | NOK 14.6M | NOK 30.9M |
| Profit before tax | NOK 80.5M | NOK 58.5M |
| Income tax expense | NOK 17.7M | NOK 12.9M |
| Profit for the year | NOK 62.7M | NOK 45.6M |
| Total comprehensive income | NOK 64.3M | NOK 49.3M |
| Per share | ||
| Basic EPS | NOK 1.42 | NOK 1.03 |
| Diluted EPS | NOK 1.42 | NOK 1.03 |
| Free cash flow / share | NOK 1.52 | NOK 1.64 |
| Cash flow statement | ||
| Net cash from operating activities | NOK 107.9M | NOK 90.6M |
| Income taxes paid | NOK 0 | NOK 0 |
| Net cash from investing activities | -NOK 40.3M | -NOK 17.7M |
| Net cash from financing activities | -NOK 81.0M | -NOK 48.1M |
| Dividends paid | NOK 77.6M | NOK 0 |
| Lease liability payments | NOK 1.2M | NOK 904.0K |
| Balance sheet | ||
| Total assets | NOK 384.9M | NOK 403.4M |
| Non-current assets | NOK 241.8M | NOK 234.6M |
| Current assets | NOK 143.2M | NOK 168.8M |
| Inventories | NOK 76.7M | NOK 80.2M |
| Trade & other receivables | NOK 44.3M | NOK 47.0M |
| Cash & equivalents | NOK 12.8M | NOK 26.2M |
| Total equity | NOK 309.5M | NOK 322.8M |
| Non-current liabilities | NOK 11.4M | NOK 11.2M |
| Current liabilities | NOK 64.0M | NOK 69.5M |
| Deferred tax liabilities | NOK 3.5M | NOK 0 |
| Derived metrics | ||
| Free cash flow | NOK 67.1M | NOK 72.7M |
| Operating margin | 19.9% | 15.8% |
| Net margin | 14.6% | 10.5% |
| Return on equity | 20.3% | 14.1% |
| Cash conversion ratio | 1.72× | 1.99× |
| Capex coverage | 2.64× | 5.06× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | NOK 3.5M | NOK 3.3M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 19.0M | NOK 17.3M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | NOK 0 | -NOK 45.1M |
| Comprehensive Income Attributable To Owners of Parent | NOK 64.3M | NOK 49.3M |
| Current Tax Liabilities Current | NOK 0 | NOK 0 |
| Deferred Tax Assets | NOK 0 | NOK 14.6M |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | NOK 19.0M | NOK 17.3M |
| Equity and Liabilities | NOK 384.9M | NOK 403.4M |
| Finance Income | NOK 9.7M | NOK 20.8M |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | NOK 451.0K | NOK 1.0M |
| Increase Decrease In Cash and Cash Equivalents | -NOK 13.4M | NOK 24.8M |
| Interest Paid Classified As Financing Activities | NOK 2.2M | NOK 2.1M |
| Interest Received Classified As Investing Activities | NOK 507.0K | NOK 220.0K |
| Issued Capital | NOK 44.3M | NOK 44.3M |
| Liabilities | NOK 75.4M | NOK 80.6M |
| Noncurrent Financial Assets | NOK 12.2M | NOK 0 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | NOK 6.6M | NOK 8.9M |
| Other Comprehensive Income | NOK 1.6M | NOK 3.7M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | NOK 2.0M | NOK 4.7M |
| Other Current Liabilities | NOK 50.9M | NOK 50.6M |
| Other Current Receivables | NOK 9.4M | NOK 15.4M |
| Other Expense By Nature | NOK 81.0M | NOK 82.6M |
| Other Noncurrent Liabilities | NOK 1.3M | NOK 2.3M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | NOK 40.8M | NOK 17.9M |
| Retained Earnings | NOK 135.9M | NOK 71.5M |
| Revenue and Operating Income | NOK 429.5M | NOK 438.3M |
| Share Premium | NOK 129.3M | NOK 206.9M |
| Trade and Other Current Payables To Trade Suppliers | NOK 13.1M | NOK 18.9M |
Every line item above is a fact tagged in VISTIN PHARMA ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.